Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

847
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
847
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

30
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
30
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

35
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
35
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

497
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
497
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

2.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of Heart Failure in Women: An Expert Consensus Statement on Sex-Specific Risk Factors.

European journal of heart failure·2026
Same author

Prevention of heart failure.

European heart journal·2026
Same author

Genetic Cascade Screening for Familial Hypercholesterolemia: A Randomized Clinical Trial.

JAMA network open·2026
Same author

Cuffless Blood Pressure Monitoring Devices: Technical Foundations and Clinical Implications.

European journal of preventive cardiology·2026
Same author

The <i>ARRplus</i>: a model for renin-dependent and sex-specific aldosterone cut-offs that improves screening for primary aldosteronism.

Clinical chemistry and laboratory medicine·2026
Same author

[2025 ESC Guidelines for the management of cardiovascular disease and pregnancy].

Giornale italiano di cardiologia (2006)·2026

Related Experiment Video

Updated: Sep 2, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

840

Hypertension and Hypercholesterolemia: Let's Make Therapy Easy and Efficient.

Isabella Sudano1

  • 1University Heart Centre, Clinic for Cardiology, University Hospital Zurich, Zurich, Switzerland.

Praxis
|August 3, 2022
PubMed
Summary

Early management of arterial hypertension and hypercholesterolemia is crucial for reducing cardiovascular risk. Single-pill combination therapies can improve patient adherence and effectively manage these conditions.

Keywords:
BluthochdruckHypercholesterinämieHypertensioncardiovascular morbidityhypercholesterolemiahypercholestérolémiekardiovaskuläre Morbiditätmorbidité cardiovasculaire

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Related Experiment Videos

Last Updated: Sep 2, 2025

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

840
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

8.2K

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • Arterial hypertension and hypercholesterolemia are significant risk factors for cardiovascular morbidity and mortality.
  • Early identification and treatment are vital for mitigating cardiovascular risk.
  • Managing multiple cardiovascular risk factors often presents adherence challenges.

Purpose of the Study:

  • To highlight the importance of early intervention in managing arterial hypertension and hypercholesterolemia.
  • To explore the potential of single-pill formulations in improving adherence for patients with multiple cardiovascular risks.

Main Methods:

  • Review of existing literature on hypertension, hypercholesterolemia, and combination therapies.
  • Analysis of adherence factors in patients with cardiovascular risk factors.

Main Results:

  • Simultaneous reduction of blood pressure and low-density lipoprotein cholesterol can significantly decrease cardiovascular risk.
  • Early intervention strategies are associated with better long-term outcomes.
  • Single-pill formulations demonstrate potential for enhancing medication adherence.

Conclusions:

  • Effective management of arterial hypertension and hypercholesterolemia, particularly when initiated early, is key to reducing cardiovascular events.
  • Single-pill combination therapies offer a promising strategy to improve adherence and manage patients with combined cardiovascular risks.